Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer



Page Path
HOME > J Liver Cancer > Volume 18(1); 2018 > Article
Review Article Systemic Therapy for Advanced Hepatocellular Carcinoma: Targeted Therapy and Immunotherapy
Kim, Bo Hyun , Park, Joong Won
Journal of Liver Cancer 2018;18(1):17-22
Published online: March 31, 2018
Center for Liver Cancer, National Cancer Center, Goyang, Korea.
  • 75 Download
  • 1 Crossref
  • 0 Scopus

Systemic therapy for hepatocellular carcinoma (HCC) has markedly changed since 2007, with the approval of sorafenib. Sorafenib improved the overall survival of patients with advanced HCC; however, the modest efficacy and toxicity of this therapy present unmet needs. Subsequently, a variety of molecular targeted agents have been tested as first-line or secondline therapies but have failed, and sorafenib has remained the only approved systemic agent for almost 10 years. Recently, regorafenib significantly improved overall survival and was approved for patients with HCC who have been previously treated with sorafenib. Nivolumab, a programmed death protein-1 inhibitor, was also approved as second-line therapy, based on remarkable response rates.

JLC : Journal of Liver Cancer